Only 2 Years of Extended Anastrozole Needed in Breast Cancer Only 2 Years of Extended Anastrozole Needed in Breast Cancer
After an initial 5 years of endocrine therapy in postmenopausal cancer, a further 2 years of the aromatase inhibitor is sufficient, instead of another 5 years, suggest new results.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Ribociclib Effective in Younger Breast Cancer Patients Too Ribociclib Effective in Younger Breast Cancer Patients Too
In premenopausal women with HR-positive, HER2-negative advanced breast cancer, the CDK4/6 inhibitor plus endocrine therapy dramatically improves progression-free survival compared with endocrine therapy alone.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Contrast-enhanced digital mammography comparable to breast MRI after therapy or chemo
(Mayo Clinic) Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news
Intermittent Letrozole Similar to Continuous Administration for Extended Breast Cancer Therapy
Taking temporary treatment breaks from letrozole following endocrine therapy for breast cancer is associated with similar disease-free survival as taking letrozole continuously, according to... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news
Breast Cancer Recurrence Still a Threat Decades After Completing 5 Years' Endocrine Therapy
Women with estrogen-receptor (ER)-positive, early-stage breast cancer who receive 5 years of adjuvant endocrine therapy are still at risk for recurrence up... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 9, 2017 Category: Primary Care Source Type: news
' Unrelenting': 20-Year Recurrence Risks in Breast Cancer'Unrelenting': 20-Year Recurrence Risks in Breast Cancer
Clinicians have new long-term data to use in discussions with patients with estrogen receptor-positive breast cancer who have been treated with 5 years of endocrine therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Fertility Concerns Impact Treatment Decisions in Breast Cancer
One - third of young women with breast cancer indicated that fertility concerns affected decisions relating to endocrine therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Breast Cancer Survivors Face Higher Risk for Hypertension, Diabetes
Risk for hypertension even higher for those receiving left - sided radiation therapy, endocrine therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Gynecology, Internal Medicine, Oncology, Radiology, Journal, Source Type: news
Response to Neoadjuvant Endocrine Therapy for Breast Cancer May Vary by Race
Race is a significant predictor of downstaging in HR+ breast cancer after adjustment for duration of NET, clinical stage (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
FDA approves new treatment for certain advanced or metastatic breast cancers
The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient ’s hormones (endocrine therapy). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2017 Category: American Health Source Type: news
Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer
(European Society for Medical Oncology) The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid (1), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone in the total study population. While most women had substantial benefit from the addition of abemaciclib as initial treatment, around one-third of women may not need a CDK 4/6 inhibitor as initial treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news
Extended AI Use Linked to CV Events and Bone Fractures Extended AI Use Linked to CV Events and Bone Fractures
There is growing interest in extending the use of adjuvant endocrine therapy in breast cancer, but the benefit vs risk for toxicity is not yet defined.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 25, 2017 Category: Cancer & Oncology Authors: Prudence A. Francis, MD Tags: Videos Breast Cancer Source Type: news
